Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival

Ugurel, Selma; Rappl, Gunter; Tilgen, Wolfgang; Reinhold, Uwe

doi:10.1200/jco.2001.19.2.577

Cited by 354 publications

(288 citation statements)

References 26 publications

Supporting

Mentioning

262

Contrasting

Unclassified

Order By: Relevance

“…In contrast, no correlation between survival and serum or plasma VEGF levels was observed. Different threshold values of serum VEGF levels have been tested, particularly 363 and 462 pg ml À1 as those values were recently described as being correlated to survival in melanoma and lymphoma (Salven et al, 2000;Ugurel et al, 2001). In this series, the median survival was 9 months for patients with VEGF levels lower than 462 pg ml À1 and 13 months for other patients (P ¼ 0.9, Figure 3).…”

Section: Prognostic Value Of Il-6 and Vegf For Overall Survivalmentioning

confidence: 73%

“…For this analysis, we tested three different threshold values for each of the two variables: the lowest quartile, the median and the highest quartile. In addition, we tested the detection limit for IL-6 and two threshold values previously reported as relevant for VEGF (Salven et al, 2000;Ugurel et al, 2001). The Cox proportional hazard regression model was used to identify independent prognostic factors for survival.…”

Section: Discussionmentioning

confidence: 99%

“…Elevated serum levels of VEGF have been found in metastatic cancer patients. These levels have been correlated to the clinical course of the disease in several tumour types (Poon et al, 2001;Ugurel et al, 2001;Molica et al, 2002). As most serum VEGF is released from platelets during blood clotting, it has been suggested that plasma VEGF may be a better reflection of ongoing angiogenic activity, although this assumption has been challenged (Banks et al, 1998;Salven et al, 1999a;Wynendaele et al, 1999;George et al, 2000).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

et al. 2003

View full text Add to dashboard Cite

Prediction of survival for patients with metastatic breast cancer is often inaccurate and may be helped by new biological parameters. Tumour growth being angiogenesis-dependent, it has been hypothesised that the assessment of angiogenic factor production might reflect the clinical behaviour of cancer progression. This study was designed to investigate the clinical significance of vascular endothelial growth factor (VEGF) and interleukin 6 (IL-6) in hormone-refractory metastatic breast cancer. Serum and plasma concentrations of VEGF and serum concentration of IL-6 were measured in 87 patients with a fully documented history of metastatic breast cancer using an enzyme-linked immunoassay. All patients had detectable levels of VEGF, whereas 39% patients had detectable serum levels of IL-6. There was a positive correlation between IL-6 levels and the theoretical VEGF load of platelets (Po0.001). The presence of high levels of serum IL-6, but not VEGF, was significantly correlated to a shorter survival. In a multivariate analysis along with clinical prognostic parameters, serum IL-6 was identified as an independent adverse prognostic variable for overall survival (Po0.001). These results indicate that serum IL-6 levels correlate to poor survival in patients with hormone-refractory metastatic breast cancer. Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients.

show abstract

Section: Prognostic Value Of Il-6 and Vegf For Overall Survivalmentioning

confidence: 73%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Elevated levels of CXCL8 have been detected in variety of tumors, such as ovarian carcinoma [157], NSCLC [158], metastatic melanoma [159], and colon carcinoma [160]. Studies from our laboratory and others suggest that the expression of CXCL8 correlates positively with disease progression [161][162][163][164].…”

Section: Chemokines and Their Receptors In Tumor Growth And Metastasismentioning

confidence: 99%

Chemokines in tumor angiogenesis and metastasis

Singh

Sadanandam

Singh

2007

Cancer Metastasis Rev

157

127

View full text Add to dashboard Cite

Chemokines are a large group of low molecular weight cytokines that are known to selectively attract and activate different cell types. Although the primary function of chemokines is well recognized as leukocyte attractants, recent evidences indicate that they also play a role in number of tumor-related processes, such as growth, angiogenesis and metastasis. Chemokines activate cells through cell surface seven trans-membranes, G-protein-coupled receptors (GPCR). The role played by chemokines and their receptors in tumor pathophysiology is complex as some chemokines favor tumor growth and metastasis, while others may enhance anti-tumor immunity. These diverse functions of chemokines establish them as key mediators between the tumor cells and their microenvironment and play critical role in tumor progression and metastasis. In this review, we present some of the recent advances in chemokine research with special emphasis on its role in tumor angiogenesis and metastasis.

show abstract

“…In patients with cancer, high serum concentrations of VEGF are associated with several unfavourable clinical parameters such as short tumour volume doubling time, progressive disease, extensive disease and poor survival (Dirix et al, 1996(Dirix et al, , 1997Salven et al, 1997a,b Kitamura et al, 1998Tempfer et al, 1998;Ugurel et al, 2001). Similarly, high concentrations of b-FGF have been detected in either urine or serum of cancer patients and associated with tumour bulk in head and neck or with a short tumour volume doubling time in colorectal cancer (O'Brien et al, 1995;Leunig et al, 1998;Kumar et al, 1998).…”

mentioning

confidence: 99%

Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia

et al. 2002

View full text Add to dashboard Cite

To assess the relative merit of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in predicting the risk of disease progression of patients with early B-cell chronic lymphocytic leukaemia we analyzed 81 Binet stage A patients whose sera were taken at the time of diagnosis and evaluated for the presence of vascular endothelial growth factor and basic fibroblast growth factor using an enzyme-linked immunosorbent assay. Serum levels of vascular endothelial growth factor positively correlated with Rai sub-stages (P=0.03), peripheral blood lymphocytosis (P=0.03), bone marrow histology (P=0.04) and b2-microglobulin (b2-m) (P=0.006). When dealing with basic fibroblast growth factor only a correlation with Rai sub-stages (P=0.02) could be found. Different cut-offs set on the basis of a stratification in quartiles, failed to demonstrate any correlation between serum levels of basic fibroblast growth factor and disease progression. In contrast, patients with increased serum levels of vascular endothelial growth factor (above median value, 203 pg ml 71 ) had a three times increased risk of disease progression, although, in multivariate analysis only Rai sub-stages (P=0.0001) and lymphocyte doubling time (P=0.002) retained their prognostic significance. Low levels of vascular endothelial growth factor were indicative of good clinical outcome in the subgroup of patients with either low (P=0.02) or high (P=0.03) b2-m concentration. Finally, the highest prognostic power was obtained when serum vascular endothelial growth factor and b2-m were examined in combination. Median of progression-free survival of patients who had both serum vascular endothelial growth factor and b2-m higher than median value was only 13 months, in contrast median progression-free survival of patients with one marker increased (i.e. above the 50th percentile) was 40 months. Patients with both markers below the median experienced the best clinical outcome (median progression-free survival not reached at 40 months). In conclusion, serum levels of either vascular endothelial growth factor or basic fibroblast growth factor are high in patients with early chronic lymphocytic leukaemia, however, only vascular endothelial growth factor predicts behaviour of disease and helps to refine the prognosis of stage A patients.

show abstract

Increased Serum Concentration of Angiogenic Factors in Malignant Melanoma Patients Correlates With Tumor Progression and Survival

Abstract: Our data suggest that the angiogenic serum factors VEGF, bFGF, and IL-8 are useful predictive markers for overall and progression-free survival in melanoma patients.

Cited by 354 publications

References 26 publications

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients

Chemokines in tumor angiogenesis and metastasis

Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia

Contact Info

Product

Resources

About